Corporate Goals and Objectives

Immediate Objectives

• Optimize the pharmacodynamics and pharmacokinetics of the peptide
  
• Determine a dose-response relationship of DT-109, Byetta, and Onglyza (dipeptidyl peptidase-4 (DPP-4) inhibitor), in a mouse diabetes model, to compare efficacy
  
• Determine if DT-109 can differentiate itself from the other compounds in a model of metabolic syndrome (ZSF-1 rats)
  

Intermediate Goals

• Complete preclinical development
  
• Identify a partner or investor consortium to fund clinical trials for DT-109
  

Long-term Goal

• Move DT-109 to global markets by leveraging co-development partnerships with large pharmaceutical companies
  

---